Andrew John Armstrong, MD

Associate Professor of Medicine
Associate Professor in Pharmacology and Cancer Biology
Associate Professor in Surgery
Member of the Duke Cancer Institute
Campus mail Duke Box 103861, Durham, NC 27710
Phone (919) 668-8797
Email address

1. Predictors of sensitivity and clinical efficacy of therapies in advanced prostate cancer
2. Novel designs of clinical trials and pharmacodynamic/translational studies in prostate, kidney, bladder cancer
3. Pre-operative models for drug development of novel agents in human testing in prostate cancer
4. Novel therapies and drug development for prostate, renal, bladder, and testicular cancer
5. Design of rational combination therapies in men with metastatic hormone-refractory prostate cancer
6. PI3 kinase/mTOR inhibition in prostate cancer: mechanisms of sensitivity and resistance
7. Developing prognostic models for progression and survival in metastatic prostate cancer
8. Examining surrogate markers of mortality in metastatic prostate cancer
9. Clear cell and non-clear cell renal cell carcinoma: natural history, sensitivity to novel agents including mTOR and VEGF inhibition

Education and Training

  • Fellowship, Division Of Oncology/Hematology, Johns Hopkins University School of Medicine, 2003 - 2006
  • Internship/Residency, General Internal Medicine, University of Pennsylvania School of Medicine, 2000 - 2003
  • M.Sc., Johns Hopkins University, 2008
  • M.D., University of Virginia School of Medicine, 2000
  • B.S.E., Duke University, 1996


Graff, JN, Baciarello, G, Armstrong, AJ, Higano, CS, Iversen, P, Flaig, TW, Forer, D, Parli, T, Phung, D, Tombal, B, Beer, TM, and Sternberg, CN. "Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAIL." Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 27, no. 2 (February 2016): 286-294.

Full Text

Tay, KJ, Moul, JW, and Armstrong, AJ. "Management of Prostate Cancer in the Elderly." Clinics in geriatric medicine 32, no. 1 (February 2016): 113-132. (Review)

Full Text

Armstrong, AJ, Halabi, S, Eisen, T, Broderick, S, Stadler, WM, Jones, RJ, Garcia, JA, Vaishampayan, UN, Picus, J, Hawkins, RE, Hainsworth, JD, Kollmannsberger, CK, Logan, TF, Puzanov, I, Pickering, LM, Ryan, CW, Protheroe, A, Lusk, CM, Oberg, S, and George, DJ. "Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial." The Lancet. Oncology (January 12, 2016).

Full Text

Armstrong, AJ, Halabi, S, Healy, P, Lee, WR, Koontz, BF, Moul, JW, Mundy, K, Creel, P, Wood, S, Davis, K, Carducci, MA, Stein, M, Hobbs, C, Reimer, B, Nguyen, M, Anand, M, Bratt, L, Kim, S, Tran, PT, and George, DJ. "A phase 2 multimodality trial of docetaxel/prednisone with sunitinib followed by salvage radiation therapy in men with PSA recurrent prostate cancer after radical prostatectomy." January 12, 2016.

Full Text

Somarelli, JA, Schaeffer, D, Marengo, MS, Bepler, T, Rouse, D, Ware, KE, Hish, AJ, Zhao, Y, Buckley, AF, Epstein, JI, Armstrong, AJ, Virshup, DM, and Garcia-Blanco, MA. "Distinct routes to metastasis: plasticity-dependent and plasticity-independent pathways." Oncogene (January 11, 2016).

Full Text

Bitting, RL, Healy, P, Halabi, S, George, DJ, Goodin, M, and Armstrong, AJ. "Clinical phenotypes associated with circulating tumor cell enumeration in metastatic castration-resistant prostate cancer." Urologic Oncology: Seminars and Original Investigations 33, no. 3 (January 1, 2016): 110.e1-110.e9.

Full Text

Harrison, MR, and Armstrong, AJ. "Burden of disease matters when it comes to systemic therapy for prostate cancer." European Urology 67, no. 3 (January 1, 2016): 448-450.

Full Text

Mohler, JL, Armstrong, AJ, Bahnson, RR, D'Amico, AV, Davis, BJ, Eastham, JA, Enke, CA, Farrington, TA, Higano, CS, Horwitz, EM, Hurwitz, M, Kane, CJ, Kawachi, MH, Kuettel, M, Lee, RJ, Meeks, JJ, Penson, DF, Plimack, ER, Pow-Sang, JM, Raben, D, Richey, S, Roach, M, Rosenfeld, S, Schaeffer, E, Skolarus, TA, Small, EJ, Sonpavde, G, Srinivas, S, Strope, SA, Tward, J, Shead, DA, and Freedman-Cass, DA. "Prostate Cancer, Version 1.2016." Journal of the National Comprehensive Cancer Network : JNCCN 14, no. 1 (January 2016): 19-30.


Zhang, T, and Armstrong, AJ. "Clinical Utility of Circulating Tumor Cells in Advanced Prostate Cancer." Current oncology reports 18, no. 1 (January 2016): 3-.

Full Text

Sonpavde, G, Pond, GR, Templeton, AJ, Fandi, A, Tombal, B, Rosenthal, M, Armstrong, AJ, and Petrylak, DP. "Association Between RECIST Changes and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Receiving Docetaxel." European urology (October 20, 2015).

Full Text